Thank you for your correspondence of 20 February to Caroline Dinenage about chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). I have been asked to reply.
I am sorry to read of your illness.
I appreciate your concerns about the PACE trial and graded exercise therapy (GET).
As you may already be aware, CFS/ME has been highlighted as a priority for the Medical Research Council (MRC) for a number of years. The MRC is currently inviting funding applications for research on biological mechanisms underlying chronic changes related to CFS/ME. This is an ongoing highlight notice with no current deadline for receipt of applications. You may wish to visit the MRC website at
www.mrc.ac.uk/funding/how-we-fund-research/highlight-notices/cfs-me-highlight-notice/.
The PACE trial undertaken by Queen Mary University of London was the largest ever trial of treatments for CFS/ME and was funded by the Medical Research Council, a non-departmental public body funded through the Government’s science and research budget. The first results from the trial were published in 2011 in The Lancet, and a number of other evaluations based on the trial have been published since.
The trial provided evidence that both cognitive behavioural therapy (CBT) and GET were moderately effective when provided alongside specialist medical care (SMC) and were better than adaptive pacing therapy or SMC alone in improving both symptoms and disability. All the treatments were found to be safe without any serious reactions to treatments in any of the treatment groups. Where patients deteriorated during the trial, this was as a result of a serious life event or infection that prompted a relapse. In 2013, a follow-up study, looking at recovery after one year, was published. This study supported the findings that CBT and GET were therapies most likely to lead to recovery.
The Government is aware that the use of CBT and GET in treating CFS/ME has long been a controversial issue for patient groups, charities and some clinicians. Since 2011, PACE trial data has been shared with many independent scientists as part of normal research collaboration, including the internationally respected research organisation Cochrane, which independently validated the findings.
Following a number of requests to the chief investigators of the PACE trial for the public release of data from the study, the Information Commissioner ruled that the Wolfson Institute at Queen Mary University of London should release this data.
The data has since been examined more widely and critics, including some clinical academics, have suggested that it shows that CBT and GET are not as effective as the trial results suggested.
The Wolfson Institute also provided trial data to a member of the public, and subsequently analysis of the data was published on a blog. The analysis has not been validated by publication in a peer-reviewed journal or other means.
The National Institute for Health and Care Excellence (NICE) is responsible for deciding whether guidance on CFS/ME should be updated.
NICE’s clinical guidelines relate to a whole pathway of care and can make a large number of recommendations spanning all stages of care from diagnosis to treatment of a condition. In view of their complexity, clinical guidelines are not subject to the same statutory funding direction as NICE’s technology appraisals. NICE clinical guidelines represent best practice. They are based on the available evidence and developed through consultation.
NICE last reviewed the guidance with its stakeholders, including CFS/ME charities, in 2013. The review found no update was required and at that time no major ongoing studies or research were identified as due to be published in the next three to five years.
Recently, NICE has been made aware of three US reports that have indicated there are likely to be changes in diagnostic criteria that could have an impact on the CFS/ME guideline recommendations and decided to start a check of whether the guideline needs updating. NICE has also been made aware of new information about the PACE trial.
The NICE guideline consultation on CFS/ME ended on 24 July and I hope you were able to contribute. Following the consultation, on 20 September, NICE announced that it would begin a review of its 2010 guideline on the diagnosis and management of CFS/ME. Further details of the review will be published shortly.
I hope this reply is helpful.
Yours sincerely,
Daniel Belmore
Ministerial Correspondence and Public Enquiries
Department of Health and Social Care